阿利鲁单抗
| 单克隆抗体 | |
|---|---|
| 种类 | ? |
| 目標 | 整合素α4β7 |
| 臨床資料 | |
| 其他名稱 | AMG 181 |
| ATC碼 |
|
| 识别信息 | |
| CAS号 | 1342290-43-0 |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化学信息 | |
| 化学式 | C6362H9806N1686O2014S52 |
| 摩尔质量 | 143,803.34 g·mol−1 |
阿利鲁单抗（INN：abrilumab；开发代号：AMG 181）是一种抗α4β7单克隆抗体，[1]设计用于治疗炎症性肠病[1]、溃疡性结肠炎[2]和克罗恩病。[3]
该药物由安进公司和阿斯利康旗下的MedImmune开发。[4]针对该药物的开发已于2016年停止。[5]
参考资料
[编辑]- ^ 1.0 1.1 Sandborn, William J.; Cyrille, Marcoli; Hansen, Mark Berner; Feagan, Brian G.; Loftus, Edward V.; Rogler, Gerhard; Vermeire, Severine; Cruz, Martha L.; Yang, Jun; Boedigheimer, Michael J.; Abuqayyas, Lubna. Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis. Gastroenterology. 2019-03, 156 (4). ISSN 1528-0012. PMID 30472236. doi:10.1053/j.gastro.2018.11.035.
- ^ Hibi, Toshifumi; Motoya, Satoshi; Ashida, Toshifumi; Sai, Souken; Sameshima, Yukinori; Nakamura, Shiro; Maemoto, Atsuo; Nii, Masahiro; Sullivan, Barbara A.; Gasser, Robert A.; Suzuki, Yasuo. Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study. Intestinal Research. 2019-07, 17 (3) [2024-05-25]. ISSN 1598-9100. PMC 6667363
. PMID 30739435. doi:10.5217/ir.2018.00141. （原始内容存档于2024-05-25）.
- ^ Pan, Wei-Jian; Köck, Kathleen; Rees, William A; Sullivan, Barbara A; Evangelista, Christine M; Yen, Mark; Andrews, Jane M; Radford-Smith, Graham L; Prince, Peter J; Reynhardt, Kaz O; Doherty, David R. Clinical pharmacology of AMG 181, a gut-specific human anti-α4β7 monoclonal antibody, for treating inflammatory bowel diseases. British Journal of Clinical Pharmacology. 2014-12, 78 (6) [2024-05-25]. ISSN 0306-5251. PMC 4256621 . PMID 24803302. doi:10.1111/bcp.12418. （原始内容存档于2024-09-25）.
- ^ Abrilumab - Amgen/AstraZeneca - AdisInsight. adisinsight.springer.com. [2024-05-25]. （原始内容存档于2017-11-01）.
- ^ abrilumab | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY. www.guidetopharmacology.org. [2024-05-25]. （原始内容存档于2024-11-30）.
